References of "European Heart Journal"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailThe EACVI Echo Handbook.
Nchimi Longang, Alain ULg

in European Heart Journal (2017)

Detailed reference viewed: 15 (1 ULg)
Full Text
Peer Reviewed
See detail2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.
Kirchhof, Paulus; Benussi, Stefano; Kotecha, Dipak et al

in European Heart Journal (2016), 37(38), 2893-2962

Detailed reference viewed: 399 (0 ULg)
Full Text
Peer Reviewed
See detail2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, Piotr; Voors, Adriaan A.; Anker, Stefan D. et al

in European Heart Journal (2016)

Detailed reference viewed: 24 (3 ULg)
Full Text
Peer Reviewed
See detail2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, Alberico L.; Graham, Ian; De Backer, Guy et al

in European Heart Journal (2016)

Detailed reference viewed: 19 (1 ULg)
Full Text
Peer Reviewed
See detail2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, Massimo F.; Hoes, Arno W.; Agewall, Stefan et al

in European Heart Journal (2016)

Detailed reference viewed: 31 (2 ULg)
Full Text
Peer Reviewed
See detailDeferral vs. performance of percutaneous coronary intervention of functionally non-significant coronary stenosis: 15-year follow-up of the DEFER trial
Zimmermann, Frederik M.; Ferrara, Angela; Johnson, Nils P. et al

in European Heart Journal (2015), 36

Deferral of PCI of a functionally non-significant stenosis is associated with a favourable very long-term follow-up without signs of late ‘catch-up’ phenomenon.

Detailed reference viewed: 39 (9 ULg)
Full Text
Peer Reviewed
See detailClinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 1: clinical trial design principles: A consensus document from the mitral valve academic research consortium.
Stone, Gregg W.; Vahanian, Alec S.; Adams, David H. et al

in European heart journal (2015), 36(29), 1851-77

Mitral regurgitation (MR) is one of the most prevalent valve disorders and has numerous aetiologies, including primary (organic) MR, due to underlying degenerative/structural mitral valve (MV) pathology ... [more ▼]

Mitral regurgitation (MR) is one of the most prevalent valve disorders and has numerous aetiologies, including primary (organic) MR, due to underlying degenerative/structural mitral valve (MV) pathology, and secondary (functional) MR, which is principally caused by global or regional left ventricular remodelling and/or severe left atrial dilation. Diagnosis and optimal management of MR requires integration of valve disease and heart failure specialists, MV cardiac surgeons, interventional cardiologists with expertise in structural heart disease, and imaging experts. The introduction of transcatheter MV therapies has highlighted the need for a consensus approach to pragmatic clinical trial design and uniform endpoint definitions to evaluate outcomes in patients with MR. The Mitral Valve Academic Research Consortium is a collaboration between leading academic research organizations and physician-scientists specializing in MV disease from the United States and Europe. Three in-person meetings were held in Virginia and New York during which 44 heart failure, valve, and imaging experts, MV surgeons and interventional cardiologists, clinical trial specialists and statisticians, and representatives from the U.S. Food and Drug Administration considered all aspects of MV pathophysiology, prognosis, and therapies, culminating in a 2-part document describing consensus recommendations for clinical trial design (Part 1) and endpoint definitions (Part 2) to guide evaluation of transcatheter and surgical therapies for MR. The adoption of these recommendations will afford robustness and consistency in the comparative effectiveness evaluation of new devices and approaches to treat MR. These principles may be useful for regulatory assessment of new transcatheter MV devices, as well as for monitoring local and regional outcomes to guide quality improvement initiatives. [less ▲]

Detailed reference viewed: 131 (0 ULg)
Full Text
Peer Reviewed
See detailThe year in cardiology 2014: valvular heart disease.
Pierard, Luc ULg; Vahanian, Alec

in European heart journal (2015)

Detailed reference viewed: 42 (2 ULg)
Full Text
Peer Reviewed
See detailCardioPulse: cardiac imaging of adult cancer patients on chemotherapy.
Galderisi, Maurizio; Lancellotti, Patrizio ULg

in European heart journal (2015), 36(15), 889-90

Detailed reference viewed: 36 (0 ULg)